Showing results (1-10 of 569) with videos related to
Sort By:
Pageof 57
Frontiers in Psychiatry|February 6, 2013
Treating depression and depression-like behavior with physical activity: an immune perspectiveHarris A Eyre, Evan Papps, Bernhard T BauneBrain, Behavior, and Immunity|November 26, 2013
Assessing for unique immunomodulatory and neuroplastic profiles of physical activity subtypes: a focus on psychiatric disordersHarris A Eyre, Bernhard T BauneProgress in Neuro-Psychopharmacology & Biological Psychiatry|December 3, 2014
A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depressionHarris A Eyre, Tracy Air, Simon Proctor, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 24, 2016
A meta-analysis of chemokines in major depressionHarris A Eyre, Tracy Air, Alyssa Pradhan, et al.International Journal of Geriatric Psychiatry|October 17, 2015
Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot studyHarris A Eyre, Ascia Eskin, Stanley F Nelson, et al.Current Topics in Behavioral Neurosciences|July 14, 2016
Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?Bernhard T BauneCurrent Medical Research and Opinion|November 24, 2023
Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapyBernhard T BauneNeuropsychiatric Disease and Treatment|April 2, 2009
New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapineBernhard T BauneCurrent Opinion in Psychiatry|January 21, 2015
Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?Bernhard T BaunePharmacogenomics|June 16, 2026
Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical useBernhard T BaunePageof 57